Arch Biopartners Closes Non-Brokered Private Placement TORONTO, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...

Arch Biopartners Receives Government of Canada Funding to Support Phase II Therapeutic Trial of Metablok for COVID-19 Government of Canada contribution up to $6.7 MillionFunding from the department of Innovation, Science and Economic Development through the Strategic Innovation Fund and part of the Government of...

Arch Biopartners Receives Ethics Committee Approval in Turkey for Phase II Trial for LSALT Peptide TORONTO, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval in Turkey from the...

Arch Biopartners Announces Application to the Turkish Ministry of Health to Conduct Phase II Trial for Treatment of Complications in COVID-19 patients TORONTO, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...